Bio-Techne (TECH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Bio-Techne

NasdaqGS•Healthcare•Biotechnology

$72.41+0.08(<0.01%)After hours

Market Cap

$11.31B

P/E

62.2x

P/S

9.3x

P/B

5.4x

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

How this company scores

GoodMetricSide Score: 76/100

Strongest: Balance Sheet & Red Flags (21/25); weakest: Growth (16/25).

Profitability18/25

Growth16/25

Balance Sheet & Red Flags21/25

Cash & Earnings Quality21/25

Strengths

Strong marginsRising earningsLow leverageCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 62.2x5y range 38.4x – 113.6x

Currently near its 20-quarter median.

P/S · 9.3x5y range 6.6x – 19.5x

Currently near its 20-quarter median.

P/B · 5.4x5y range 3.9x – 11.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Price & Volume

Market Cap $11.31B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.22B
Q. Revenue: $321.19M
TTM EBITDA: $349.25M
TTM Op. Income: $251.89M
Q. Op. Income: $74.28M
TTM Net Income: $181.86M
Q. Net Income: $54.62M
EPS: $0.35
Shares Out.: $156.22M

$1.22B in TTM revenue declined 0.4% YoY, reaching $321.19M last quarter. TTM EBITDA of $349.25M and TTM operating income of $251.89M show growth is flowing through to the bottom line. TTM net income of $181.86M means revenue is converting into profit. Over the past year, TTM revenue is down 0% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 65.8%
EBITDA Margin: 30.6%
Op. Margin: 23.1%
Net Margin: 17.0%

Op. margin of 23.1% is up 30.7% YoY — cost efficiency is improving. Net margin at 17.0% and gross margin of 65.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 407% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 62.2x
P/S Ratio: 9.3x
P/B Ratio: 5.4x

At 62.2x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 9.3x and P/B of 5.4x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.59B
Cash: $264.71M
Long-Term Debt: $200.00M
Book Value: $2.11B
D/E Ratio: 0.1
Debt/EBITDA: 2.0

With $2.59B in assets and $200.00M in long-term debt, D/E is 0.1and book value is $2.11B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 4 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $95.42M
TTM Free Cash Flow: $263.22M
FCF Margin: 21.7%
FCF / Net Income: 1.4

TTM FCF of $263.22M on $95.42M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 3% — a weakening trend.